TheraTech Inc., 417 Wakara Way, and Procter & Gamble have applied in Canada and the United Kingdom to have their estrogen replacement therapy patch approved for sale.
In December 1995, the companies filed an application with the U.S. Food and Drug Administration to market the product in the United States under the name ALORA.ALORA will be the first product that goes to market under a 1995 agreement that allows Procter & Gamble the right to market the TheraTech-developed system worldwide (except in Asia).
While transdermal systems currently represent only about 11 percent of the United States hormone replacement therapy market, they are expected to become more popular as physicians and patients gain awareness of ALORA, company officials said.
Worldwide, the total hormone replacement therapy market is estimated at $1.9 billion.
TheraTech's patented matrix transdermal technology is thin, flexible and transparent.